ROIVANT SCIENCES LTD. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
ROIVANT SCIENCES LTD. (ROIV) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 50.73 thousand shares for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2026-05-20
- ROIVANT SCIENCES LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-03-31 was 0.00 shares.
- ROIVANT SCIENCES LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-12-31 was 0.00 shares.
- ROIVANT SCIENCES LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-09-30 was 0.00 shares.
- ROIVANT SCIENCES LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-06-30 was 50.73K shares.
- ROIVANT SCIENCES LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2026 was 50.73K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2026-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | 0.00 shares derived: sum of 2 quarters · filed 2026-05-20 | 0.00 shares derived: sum of 3 quarters · filed 2026-05-20 | 50.73K shares 10-K · filed 2026-05-20 |
| 2025-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-06 | 50.73K shares 10-Q · filed 2026-02-06 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | 50.73K shares 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | 50.73K shares 10-Q · filed 2025-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |